The Hall of Fame voting for 2025 will be completed before Super Bowl week. Giants quarterback Eli Manning is on the ballot for the first time. And there’s a decent chance that Eli will be waiting at ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

RICHARDSON, Texas (KLTV) - Former Big Sandy Wildcat Eli Beard lead Mary Hardin-Baylor in scoring, but the Cru fell short in their comeback attempt falling to UT-Dallas 72-69. The senior was a perfect ...

He was also a constant thorn in the side of the Romo-era Cowboys, going 8-3 from 2008-2012. Among his notable wins against Dallas were the first-ever game at then-Cowboys Stadium in Arlington in ...

Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation ...

Is Eli Manning a Hall of Famer ... The former safety won three Super Bowls during the 1990s with the Dallas Cowboys and earned four first-team All-Pro selections. He’s the franchise’s all ...

Eli Manning moved one step closer to football immortality Saturday, as he was named one of 15 finalists for the Pro Football Hall of Fame’s Class of 2025. Manning, the former No. 1-overall pick ...

Former New York Giants quarterback Eli Manning, tight end Antonio Gates and receiver Reggie Wayne are three of 15 players selected as finalists for the 2025 class, the Hall of Fame announced on ...

Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Johnson & Johnson, Moderna, and Novo Nordisk.